Literature DB >> 16224247

Damage and inflammation in muscular dystrophy: potential implications and relationships with autoimmune myositis.

James G Tidball1, Michelle Wehling-Henricks.   

Abstract

PURPOSE OF REVIEW: This review provides an updated evaluation of the role of inflammation in muscular dystrophy, and presents findings which suggest that non-immunological factors promote idiopathic inflammatory myopathies. Recent findings are summarized which indicate that immune-targeted interventions may provide useful approaches to treat muscular dystrophy. RECENT
FINDINGS: Elevated expression of the cytotoxic T-lymphocyte derived cytolytic molecule, perforin, and the inducible costimulatory molecule have been identified in muscles of Duchenne muscular dystrophy patients, which strengthens evidence that a cellular immune response contributes to dystrophinopathy. Conversely, new findings implicate non-immune factors in inflammatory myopathy pathogenesis. Muscles from healthy individuals expressed autoantigens typically present in inflammatory myopathies, and autoantigen expression increased along with elevated major histocompatibility complex class I expression at sites of muscle regeneration in inflammatory myopathies. Those observations suggest that regeneration could render conditions sufficient for an autoimmune response in inflammatory myopathies. Further studies of corticosteroids or tumor necrosis factor blockade in treating dystrophinopathy indicate that immunological interventions may yield improved therapies for muscular dystrophy. In addition, advancements in understanding the involvement of chemokines in muscular dystrophy and inflammatory myopathies suggest that targeting specific chemokines has potential therapeutic value.
SUMMARY: Our developing understanding of the pathogenesis of muscular dystrophies and inflammatory myopathies shows complex interactions between immunological and non-immunological features of these diseases that can affect disease onset and course. Among the muscular dystrophies, the best evidence for an immunological component to disease pathogenesis exists for dystrophinopathies. Conversely, muscle damage leading to regeneration may promote some inflammatory myopathies, although much remains to be learned concerning the identity and pathological significance of non-immunological features of inflammatory myopathies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16224247     DOI: 10.1097/01.bor.0000179948.65895.1a

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  31 in total

1.  Predicting steroid response in muscle disease.

Authors:  N Nirmalananthan; M G Hanna
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-10       Impact factor: 10.154

2.  Osteopontin-stimulated expression of matrix metalloproteinase-9 causes cardiomyopathy in the mdx model of Duchenne muscular dystrophy.

Authors:  Saurabh Dahiya; Srikanth Givvimani; Shephali Bhatnagar; Natia Qipshidze; Suresh C Tyagi; Ashok Kumar
Journal:  J Immunol       Date:  2011-08-01       Impact factor: 5.422

3.  The dual roles of neutrophils and macrophages in inflammation: a critical balance between tissue damage and repair.

Authors:  Timothy A Butterfield; Thomas M Best; Mark A Merrick
Journal:  J Athl Train       Date:  2006 Oct-Dec       Impact factor: 2.860

4.  Signs of inflammation in both symptomatic and asymptomatic muscles from patients with polymyositis and dermatomyositis.

Authors:  C Dorph; P Englund; I Nennesmo; I E Lundberg
Journal:  Ann Rheum Dis       Date:  2006-07-10       Impact factor: 19.103

5.  Icing treatment in rats with crush syndrome can improve survival through reduction of potassium concentration and mitochondrial function disorder effect.

Authors:  Isamu Murata; Mayuki Imanari; Marise Komiya; Jun Kobayashi; Yutaka Inoue; Ikuo Kanamoto
Journal:  Exp Ther Med       Date:  2019-11-22       Impact factor: 2.447

6.  MAP kinase phosphatase-1 deficiency impairs skeletal muscle regeneration and exacerbates muscular dystrophy.

Authors:  Hao Shi; Emmanuel Boadu; Fatih Mercan; Annie M Le; Rachel J Roth Flach; Lei Zhang; Kristina J Tyner; Bradley B Olwin; Anton M Bennett
Journal:  FASEB J       Date:  2010-04-06       Impact factor: 5.191

7.  Insights into bone health in Duchenne muscular dystrophy.

Authors:  Victor H Morgenroth; Lauren P Hache; Paula R Clemens
Journal:  Bonekey Rep       Date:  2012-02-01

8.  Multi-parametric MRI characterization of inflammation in murine skeletal muscle.

Authors:  Nathan D Bryant; Ke Li; Mark D Does; Stephanie Barnes; Daniel F Gochberg; Thomas E Yankeelov; Jane H Park; Bruce M Damon
Journal:  NMR Biomed       Date:  2014-04-29       Impact factor: 4.044

Review 9.  Gene therapy in large animal models of muscular dystrophy.

Authors:  Zejing Wang; Jeffrey S Chamberlain; Stephen J Tapscott; Rainer Storb
Journal:  ILAR J       Date:  2009

Review 10.  Immune-mediated mechanisms potentially regulate the disease time-course of duchenne muscular dystrophy and provide targets for therapeutic intervention.

Authors:  Nicholas P Evans; Sarah A Misyak; John L Robertson; Josep Bassaganya-Riera; Robert W Grange
Journal:  PM R       Date:  2009-08       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.